<DOC>
	<DOC>NCT02100696</DOC>
	<brief_summary>This phase III, double blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission in participants with moderately to severely active ulcerative colitis (UC) who are refractory to or intolerant of TNF inhibitors.</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Moderately to severely active UC as determined by the Mayo Clinic Score assessment (MCS) Intolerance, loss response or failure to respond to treatment with at least one TNFinhibitor within the previous 5 years Washout of antiTNF therapy for at least 8 weeks preceding Day 1 Background regimen for UC may include oral 5aminosalicylic acid (5ASA), oral corticosteroids, budesonide multimatrix system (MMX), probiotics, azathioprine (AZA), 6mercaptopurine (6MP), or methotrexate (MTX) if doses have been stable during the screening period Use of highly effective contraception as defined by the protocol Must have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening A history of or current conditions and diseases affecting the digestive tract, such as indeterminate colitis, Crohn's disease, fistulas or abdominal abscesses, colonic mucosal dysplasia, intestinal obstruction, toxic megacolon, or unremoved adenomatous colonic polyps Prior or planned surgery for UC Past or present ileostomy or colostomy Any prior treatment with etrolizumab or other antiintegrin agents (including natalizumab, vedolizumab, and efalizumab) and rituximab Chronic hepatitis B or C infection, human immunodeficiency virus (HIV) or tuberculosis Evidence of or treatment for Clostridium difficile clinically significant cytomegalovirus (CMV) colitis within 60 days prior to Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>